Healthcare / BiotechnologyNasdaqGM
$8.51
+0.21 (+2.53%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-34.7M · quality 59.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
32/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$624M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-73.5%
↓Gross Margin
N/A
•Debt/Equity
0.94
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
1.02x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-38.2M · FCF $-38.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | — | — | — | — | $125000.00 | $125000.00 | $125000.00 |
| Net Income | $-38.2M | $-38.2M | $-55.2M | $-37.9M | $-18.8M | $-36.1M | $-17.7M |
| EBITDA | $-35.2M | $-35.2M | $-52.1M | $-34.4M | $-16.3M | $-25.5M | $-13.7M |
| EPS | — | — | -1.74 | -1.31 | -0.65 | -1.91 | — |
| Operating Margin | — | — | — | — | -27739.2% | -20580.8% | -11048.0% |
| Net Margin | — | — | — | — | -15035.2% | -28899.2% | -14144.0% |
| Balance Sheet | |||||||
| Debt/Equity | 0.94 | 0.94 | 0.20 | 1.79 | 0.48 | 0.01 | -0.02 |
| Current Ratio | 28.05 | 28.05 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-38.9M | $-38.9M | $-27.0M | $-34.7M | $-32.7M | $-24.1M | $-10.5M |
| Returns | |||||||
| ROE | -73.5% | -73.5% | -83.2% | -297.7% | -39.4% | -56.3% | 75.0% |
| Valuation | |||||||
| P/B | 9.00 | 9.00 | 4.40 | 3.20 | 1.20 | — | — |
| Growth & Yield | |||||||
| Revenue Growth | — | — | — | — | — | 0.0% | — |
| EPS Growth | — | — | -32.8% | -101.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+56.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.74 → n/d
Residual
+56.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.